Virbac SA
Research Virbac SA (VIRP) on Bullrun: market cap EUR 2.78B, P/E 18.4, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVIRP
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyEUR
- Market capEUR 2.78B
- P/E18.4
- Dividend yield0.5%
- Financial periodFY2025
- RevenueEUR 1.46B
- Revenue growth4.8%
- Net incomeEUR 150.89M
- Free cash flowEUR 96.85M
- Gross margin66.6%
Valuation Snapshot
latest market cap is EUR 2.78B; P/E is 18.4; dividend yield is 0.5%.
Peer valuation comparison
Latest P/E is 18.42x versus a Healthcare sector median of 24.46x (24.7% below).
Latest dividend yield is 0.45% versus a Healthcare sector median of 2.11% (78.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 1.46B | EUR 150.89M | EUR 96.85M | 66.6% | 18 | EUR 122.50M | EUR 288.83M | EUR 1.13B |
| FY2024 | EUR 1.40B | EUR 145.29M | EUR 123.78M | 67.1% | 17.34 | EUR 149.63M | EUR 307.01M | EUR 1.04B |
| FY2023 | EUR 1.25B | EUR 121.30M | EUR 58.74M | 64.9% | 14.38 | EUR 175.91M | EUR 120.11M | EUR 900.30M |
| FY2022 | EUR 1.22B | EUR 121.94M | EUR 45.41M | 65.0% | 14.42 | EUR 177.38M | EUR 90.40M | EUR 839.64M |
| FY2021 | EUR 1.06B | EUR 113.16M | EUR 82.74M | 65.9% | 13.38 | EUR 172.79M | EUR 94.47M | EUR 724.94M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 2.78B | 18.4 | 0.4% | 1.45 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.45 EUR, yield 0.5%.
| Year | Dividends/share |
|---|---|
| FY2025 | 1.45 EUR |
| FY2024 | 1.32 EUR |
| FY2023 | 1.32 EUR |
| FY2022 | 1.25 EUR |
| FY2021 | 0.75 EUR |
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Virbac SA's market cap?
Virbac SA's market capitalization is EUR 2.78B.
What is Virbac SA's P/E ratio?
Virbac SA's price-to-earnings (P/E) ratio is 18.4.
Does Virbac SA pay a dividend?
Virbac SA has a dividend yield of 0.5%.
What does Virbac SA do?
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific.